Approaching a diagnostic point-of-care test for pediatric tuberculosis through evaluation of immune biomarkers across the clinical disease spectrum. |
Authors: |
Jenum, Synne Dhanasekaran, S Lodha, Rakesh Mukherjee, Aparna Kumar Saini, Deepak Singh, Sarman Singh, Varinder Medigeshi, Guruprasad Haks, Marielle C Ottenhoff, Tom H M Doherty, Timothy Mark Kabra, Sushil K Ritz, Christian Grewal, Harleen M S
|
Citation: |
Jenum S, etal., Sci Rep. 2016 Jan 4;6:18520. doi: 10.1038/srep18520. |
RGD ID: |
124715450 |
Pubmed: |
PMID:26725873 (View Abstract at PubMed) |
PMCID: |
PMC4698754 (View Article at PubMed Central) |
DOI: |
DOI:10.1038/srep18520 (Journal Full-text) |
The World Health Organization (WHO) calls for an accurate, rapid, and simple point-of-care (POC) test for the diagnosis of pediatric tuberculosis (TB) in order to make progress "Towards Zero Deaths". Whereas the sensitivity of a POC test based on detection of Mycobacterium tuberculosis (MTB) is likely to have poor sensitivity (70-80% of children have culture-negative disease), host biomarkers reflecting the on-going pathological processes across the spectrum of MTB infection and disease may hold greater promise for this purpose. We analyzed transcriptional immune biomarkers direct ex-vivo and translational biomarkers in MTB-antigen stimulated whole blood in 88 Indian children with intra-thoracic TB aged 6 months to 15 years, and 39 asymptomatic siblings. We identified 12 biomarkers consistently associated with either clinical groups "upstream" towards culture-positive TB on the TB disease spectrum (CD14, FCGR1A, FPR1, MMP9, RAB24, SEC14L1, and TIMP2) or "downstream" towards a decreased likelihood of TB disease (BLR1, CD3E, CD8A, IL7R, and TGFBR2), suggesting a correlation with MTB-related pathology and high relevance to a future POC test for pediatric TB. A biomarker signature consisting of BPI, CD3E, CD14, FPR1, IL4, TGFBR2, TIMP2 and TNFRSF1B separated children with TB from asymptomatic siblings (AUC of 88%).
|
|